Brain Imaging Lab
The Brain Imaging Lab is housed in the Molecular Imaging and Neuropathology Division at the New York State Psychiatric Institute and the Department of Psychiatry at Columbia University Irvine Medical Center. The lab conducts studies that increase our understanding of the neurobiology of mood disorders and suicide and the mechanisms of medication and psychotherapeutic interventions with a goal to develop more effective treatments. The lab also focuses on the development and application of a wide range of computational tools and statistical methods to address these topics using multimodal neuroimaging (functional, structural and molecular in vivo neuroimaging) and genomics data in healthy humans and patients with mood disorders.
Jeffrey Miller, MD
Associate Professor of Clinical Psychiatry
Dr. Miller is an Associate Professor of Clinical Psychiatry at Columbia University and conducts multimodal brain imaging research investigating biological correlates of depression and suicide risk using Positron Emission Tomography (PET) and magnetic resonance imaging (MRI). In addition, he uses brain imaging to predict treatment outcome, with a long term goal of contributing to personalized medicine in psychiatry. He codirects a brain imaging laboratory devoted to these goals.
Dr. Miller has investigated pathophysiology in major depressive disorder using PET imaging to quantify relevant neurochemical systems, including the serotonin and kappa opioid neurotransmitter systems. He has conducted studies related to the pathophysiology of major depressive disorder, using PET imaging to focus on the serotonin and kappa opioid neurotransmitter systems. With colleagues, he has found consistent and replicated evidence of trait abnormalities of elevated 5-HT1A receptor binding in major depressive disorder, that are present both during active illness as well as during periods of sustained remission. He conducted the first study quantifying the kappa opioid receptor in major depressive disorder, identifying a trend-level relationship between kappa opioid receptor binding and activation of the hypothalamic-pituitary-adrenal axis. In currently funded work, he is investigating markers of neuroinflammation and of neurotransmitter catabolism in the pathophysiology of depression and suicide risk.
Identifying predictors of treatment outcome in psychiatry is an urgent clinical issue given the inadequate response and remission rates to existing treatments, the limited ability that clinicians have presently to predict treatment outcome, and the high morbidity that results from ineffectively treated illness. Dr. Miller’s work has used PET imaging to identify serotonergic abnormalities that predict better response to serotonergic antidepressants. He has also identified predictors of outcome to medication-based and psychotherapeutic treatment for depression using functional MRI and diffusion tensor imaging.
Francesca Zanderigo, PhD
Associate Professor of Clinical Neurobiology (in Psychiatry)
Dr. Francesca Zanderigo, PhD, is a Bioengineer, Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University, and the Director of the Laboratory of Image Analysis within Brain Imaging in the Molecular Imaging and Neuropathology (MIND) Area at the New York State Psychiatric Institute (NYSPI). She has worked for over 15 years now in the field of medical imaging research, performing extensive quantification, mathematical modeling and analysis of brain images and data from both Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) for the investigation of cerebral hemodynamics and neuroreceptor systems. Dr. Zanderigo's research focuses on the extraction of accurate quantitative information from medical data and images, for the purpose of improving disease diagnosis and treatment. This includes the development of sophisticated methods for data quantification that simplify the acquisition of Positron Emission Tomography (PET) images, while maintaining accuracy and precision of the information extracted from such images, with the aim of promoting the translation of PET technique into clinical practice. These advanced methods allow investigators to reduce, and in some cases, eliminate the need for arterial blood sampling during imaging with PET, and have been applied to PET radiotracers used to image, for example, the translocator protein, monoamine oxidase A, the incorporation of arachidonic acid, the serotonin 1A receptor and transporter, and glucose metabolism. Further contributions from Dr. Zanderigo include creating approaches that overcome the problem posed by many targets of PET imaging, the absence of a valid reference region, to provide measurements of PET binding that are specific only to the target of interest. As well, her work includes developing other advanced methodologies in the field of in vivo brain imaging, ranging in scope from the generation of quantitative parametric images at the voxel level, to data-adaptive robust fitting approaches to improve statistical power and sensitivity of imaging studies, to model-free quantification for PET images. Dr. Zanderigo is currently Principal Investigator of an R01 funded by the National Institute of Biomedical Imaging and Bioengineering that aims at developing noninvasive quantification methods for data acquired with next-generation portable PET cameras. A complete list of Dr. Zanderigo’s publications can be found at the following link: https://scholar.google.com/citations?user=L3uS04cAAAAJ&hl=en
Principal Investigators and Faculty
Todd Ogden, PhD
Professor, Biostatistics (in Psychiatry)
I am interested in statistical modeling of imaging data and, more broadly, in modeling of functional data and other high dimensional data sources. A major focus of my recent work is on development of modeling solutions to various problems that arise in PET imaging applications. Recent contributions in that area have involved simultaneous (across regions and/or across subjects) modeling, methods for relaxing modeling assumptions, and non-parametric alternatives to the popular kinetic modeling approaches.
Spiro P. Pantazatos, PhD
Assistant Professor of Clinical Neurobiology (in Psychiatry)
I have interests and experience in translational neuroinformatics, computational neuroimaging and psychiatric genomics. My work includes development and application of computational tools to accelerate mental health research. A primary research track applies data mining to brain imaging, molecular neuroanatomy and genomics data to identify and understand the etiology of anxiety, mood disorders and suicide in order to help guide treatment development for these disorders. I am also spearheading development of My Brain and Me, a web interface to crowdsource brain imaging and behavioral data while allowing participants to explore their own brain. The goal is to create a scalable approach that speeds up neuroimaging and mental health research and also increases public awareness and engagement with neuroscience. Other ongoing interests include birth season and neurobehavioral traits, political psychology and cognitive neuroscience, intuition and psychoinformatics. My publications can be accessed on Researchgate.
Dongrong Xu, PhD
Associate Professor of Clinical Neurobiology (in Psychiatry)
Dongrong Xu's research interests are developing novel algorithms and methods for neuroimaging data analysis, and their applications to various neuroscience, psychiatric and neurological studies. Dr. Xu also develops virtual reality paradigms for neuroimaging studies. Please see the following link for more details and his recent publications: http://www.columbia.edu/~dx2103/
Zhengchao Dong, PhD
Associate Professor of Clinical Neurobiology (in Psychiatry)
MR physics and MRI methodology
- MRI image reconstruction and processing
- MR spectroscopic imaging techniques
Applications of MRI in
- Mental disorders
- Metabolism and physiology
Collaborating with colleagues on projects involving magnetic resonance spectroscopy (MRS). The MRS work includes:
- Quantification of dynamic changes of metabolites during drug infusion/administration in patients with depression or bipolar disorders
- Quantification of change of metabolite levels in response to treatment in patients with depression or bipolar disorders.
MRI methodology development
- Dynamic or functional MRS
- 1H MRS-based thermometry
- 1H MRS imaging without water suppression
- Magnetic resonance fingerprinting and MR spectroscopic fingerprinting
M. Elizabeth Sublette, MD, PhD
Associate Professor of Clinical Psychiatry
Dr. Sublette has a longstanding interest in brain mechanisms underlying mood disorders and suicide risk. She is particularly focused on the mechanisms of action of polyunsaturated fatty acids (PUFAs) on the brain. Her research in these areas encompasses a broad variety of translational approaches, including not only neuroimaging but clinical, biochemical, , genetic and epigenetic methodologies. Dr. Sublette is the Director of the Molecular Imaging and Neuropathology Division (MIND) Research Clinic and Core Leader for the Clinical Evaluation Core of the MIND Silvio O. Conte Center for Basic or Translational Mental Health Research (MH090964). In studying brain mechanisms related to PUFAs, depression and suicide risk, Dr. Sublette’s work has utilized multiple neuroimaging modalities, including structural magnetic resonance imaging (MRI), positron emission tomography (PET) and diffusion tensor imaging (DTI):
Gopaldas, M., Zanderigo, F., Zhan, S., Ogden, R.T., Miller, J.M., Rubin-Falcone, H., Cooper, T.B., Oquendo M.A., Sullivan, G., Mann, J.J., Sublette, M.E., “Brain serotonin transporter binding, plasma arachidonic acid and depression severity: A positron emission tomography study of major depression.” Journal of Affective Disorders, in press.
Zanderigo, F., Kang, Y., Kumar, D., Nikolopoulou, A., Mozley, P.D., Kothari, P., He, B., Schlyer, D., Rapoport, S., Oquendo, M., Vallabhajosula, S., Mann, J.J., Sublette, M.E., “[11C]arachidonic acid incorporation measurement in human brain: optimization for clinical use." Synapse (2018) 72(2). doi: 10.1002/syn.22018. Epub 2017 Nov 27. PubMed PMID: 29144569; PubMed Central PMCID: PMC6075823.
Chhetry B.T., Hezghia A., Miller J.M., Lee S., Rubin-Falcone H., Cooper T.B., Oquendo M.A., Mann J.J., Sublette M.E., “Omega-3 polyunsaturated fatty acid supplementation and white matter changes in major depression.” Journal of psychiatric research (2016) 75:65-74. PMCID:PMC4948754
Sublette, M.E., Milak, M.S., Galfalvy, H.C., Oquendo, M.A., Malone, K.M., Mann, J.J., “Regional brain glucose uptake distinguishes suicide attempters from non-attempters in Major Depression.” Archives of Suicide Research (2013) 17(4):434-447. PMCID: PMC3831169
Sublette, M.E., Milak, M.S., Hibbeln, J.R., Freed, P.J., Oquendo, M.A., Malone, K.M., Parsey, R.V., John Mann, J., “Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression.” Prostaglandins Leukotrienes & Essential Fatty Acids (2009) 80(1):57-64. PMCID: PMC2712826
Fellows and Assistant Research Scientists
Mina Rizk, M.B.B.Ch., MS
Paul Janssen Translational Neuroscience Postdoctoral Research Fellow
Mina Rizk completed his medical degree and psychiatry residency at Minia University, Egypt. He is currently doing his postdoctoral research training on a prospective NIH-funded study investigating the neurobiological underpinnings of suicidal subgroups. For the past three years, Dr. Rizk’s research has been focusing on understanding the brain and neuroendocrinological correlates of different clinical and cognitive aspects of depression and suicidality. He has received the Paul Janssen postdoctoral fellowship in translational neuroscience research and will start collaborating with the Division on Substance Abuse on a project examining the functional brain mechanisms underlying the anti-suicidal effects of buprenorphine in opioid use disorder patients at high-risk for suicidal behavior. This may help refine the use of buprenorphine or other opioid-active compounds in treatment of suicidality. A complete list of Dr. Rizk’s publications can be found at the following link: https://scholar.google.com/citations?user=iSuWTScAAAAJ&hl=en
Mike Schmidt, PhD
Postdoctoral Research Scientist
Mike Schmidt has spent most of his life wondering how the brain makes us who we are. He started out academically in computer science, then moved to exercise physiology. After working in banking and video game development for several years, he spent nearly a decade child-rearing and watching neuro-developmental milestones happen in front of him. He then earned his PhD in neuroscience by investigating how the hippocampus changes in aging and cognitive decline with the wonderful people at The University of Mississippi Medical Center. In addition to helping Dr. Pantazatos with My Brain and Me, he is currently working with Dr. Pantazatos to figure out which genes are most important for supporting connectivity in peoples' brains. He thinks a stronger background in philosophy and mathematics would give him a deeper understanding of everything.
Louisa Steinberg, MD, PhD
Dr. Steinberg completed her residency training in psychiatry at Columbia University & the New York State Psychiatric Institute. She is currently a T32 funded research fellow in mood and anxiety disorders. Dr. Steinberg's research focuses on studying the underlying neural dysfunction in depression and how to improve treatment outcomes for patients using brain imaging. Currently, she is examining how BOLD responses in primary auditory cortex and cortical GABA levels are altered in major depressive disorder and whether these measures can be used to predict treatment response to SSRIs.
Katie Surrence, MS
Assistant Research Scientist
Katie Surrence received her MS in psychology from UW-Madison where she worked in a lab devoted to understanding the effects of child abuse and neglect. Since then she has worked in New York City as a researcher, therapist, software developer, and professor. Her research collaborators have included Regina Miranda, in work on how thought patterns can predict later suicidal ideation, and currently Andrew Gerber, as data analyst on an fMRI study of transference -- the experience of importing your expectations from previous relationships onto someone new. She has worked as a therapist in Depression Evaluation Services at New York State Psychiatric Institute and currently in NYSPI's Gambling Disorders clinic. She taught Abnormal Psychology at John Jay College of Criminal Justice, and she worked as a software developer at Spring Health, a company that provides a tele-mental health platform. Right now in the lab she is collaborating with Spiro Pantazatos and Mike Schmidt on building My Brain and Me. When she isn't working on any of that she likes drawing comics, studying voice, and going to -- and occasionally teaching -- yoga. She understands all of the above as an investigation of how the mind interacts with the world outside it.
Cheung S, Goldenthal AR, Uhlemann A-C, Mann JJ, Miller JM, Sublette E. Systematic Review of Gut Microbiota and Major Depression. Frontiers in Psychiatry, section Mood and Anxiety Disorders (2019): in press.
Rubin-Falcone H, Weber J, Kishon R, Ochsner K, Delaparte L, Doré B, Raman S, Denny BT, Oquendo MA, Mann JJ, Miller JM. Neural predictors and effects of cognitive behavioral therapy for depression: the role of emotional reactivity and regulation. Psychological Medicine (2019); 11: 1-15.
Miller JM, Zanderigo F, Purushothaman PD, DeLorenzo C, Rubin-Falcone H, Ogden RT, Keilp J, Oquendo MA, Nabulsi N, Huang YH, Parsey RV, Carson RE, Mann JJ. Kappa Opioid Receptor Binding in Major Depression: A Pilot Study. Synapse (2018); 72(9): e22042.
Rubin-Falcone H, Weber J, Kishon R, Ochsner K, Delaparte L, Doré B, Zanderigo F, Oquendo MA, Mann JJ, Miller JM. Longitudinal effects of cognitive behavioral therapy for depression on the neural correlates of emotion regulation. Psychiatry Research: Neuroimaging (2018); 271: 82-90.
Milak MS, Pantazatos S, Rashid R, Zanderigo F, Delorenzo C, Hesselgrave N, Ogden RT, Oquendo MA, Mulhern ST, Miller JM, Burke AK, Parsey RV, Mann JJ. Higher 5-HT1A autoreceptor binding as an endophenotype for major depressive disorder identified in high risk offspring – A pilot study. Psychiatry Research: Neuroimaging (2018); 276: 15-23.
Zanderigo F, Pantazatos S, Rubin-Falcon H, Ogden RT, Chhetry BT, Sullivan G, Oquendo M, Miller JM, Mann JJ. In vivo relationship between serotonin 1A receptor binding and gray matter volume in the healthy brain and in major depressive disorder. Brain Struct Funct (2018); 223(6):2609-2625
Rubin-Falcone H, Zanderigo F, Thapa-Chhetry B, Lan M, Miller JM, Sublette ME, Oquendo MA, Hellerstein DJ, McGrath PJ, Stewart JW, Mann JJ. Pattern recognition of magnetic resonance imaging-based gray matter volume measurements classifies bipolar disorder and major depressive disorder. Journal of Affective Disorders (2018); 227: 498-505.
Metts AV, Keilp JG, Oquendo MA, Mann JJ, Miller JM. Neurocognitive performance predicts treatment outcome with cognitive behavioral therapy for major depressive disorder. Psychiatry Research (2018); 269: 376-385. PMID: 30173044.
Miller JM, Everett BA, Oquendo MA, Ogden RT, Mann JJ, Parsey RV. Positron emission tomography quantification of serotonin transporter binding in medication-free bipolar disorder. Synapse (2016); 70(1): 24-32.
Schneck N, Miller JM, Delorenzo C, Kikuchi T, Sublette ME, Oquendo MA, Mann JJ, Parsey RV. Relationship of the serotonin transporter gene promoter polymorphism (5-HTTLPR) genotype and serotonin transporter binding to neural processing of negative emotional stimuli. J Affect Disord (2016); 190:494-8.
Oquendo MA, Galfalvy H, Sullivan GM, Miller JM, Milak MM, Sublette ME, et al (2016). Positron Emission Tomography Imaging of the Serotonergic System and Prediction of Risk and Lethality of Future Suicidal Behavior JAMA Psychiatry (2016); 73(10): 1048-1055.
Miller JM, Hesselgrave N, Ogden RT, Sullivan GM, Oquendo MA, Mann JJ, Parsey RV. Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biological Psychiatry (2013); 74: 287-95. PMCID: PMC3725207
Miller JM, Hesselgrave N, Ogden RT, Zanderigo, F, Oquendo MA, Mann JJ, Parsey RV. Brain Serotonin 1A receptor binding as a predictor of treatment outcome in major depressive disorder. Biological Psychiatry (2013); 74: 760-7. PMCID: PMC4066966.
Miller JM+, Schneck N+, Siegle GJ, Chen Y, Ogden RT, Kikuchi T, Oquendo MA, Mann JJ, Parsey RV. fMRI response to negative words and SSRI treatment outcome in major depressive disorder: a preliminary study. Psychiatry Research: Neuroimaging (2013; 214: 296-305. PMCID: PMC4083855. (+ = co-first authors)
Kikuchi T, Miller JM, Schneck N, Oquendo MA, Mann JJ, Parsey RV, Keilp JG. Neural responses to incongruency in a blocked-trial Stroop task in major depressive disorder. Journal of Affective Disorders (2012); 143: 241-7. PMCID: PMC3501555.